Infinity Pharmaceuticals Stock Sees Short Interest Move 13% Lower

The most recent short interest data has been released by the NASDAQ for the 08/15/2014 settlement date, which shows a 536,770 share decrease in total short interest for Infinity Pharmaceuticals Inc ( INFI), to 3,591,594, a decrease of 13.00% since 07/31/2014. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for INFI at the 08/15/2014 settlement increased to 799,884, as compared to 528,708 at the 07/31/2014 report. That brought "days to cover" down to 4.49, a 42.50% decrease from the 7.81 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for INFI at previous short interest release dates:

Top 25 S.A.F.E. Dividend Stocks »

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where INFI had been shorted as a hedge.

The chart below shows the one year performance of INFI shares, versus its 200 day moving average. Looking at this chart, INFI's low point in its 52 week range is $8.40 per share, with $21.60 as the 52 week high point — that compares with a last trade of $11.67.

If you liked this article you might like

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

5 Stocks Insiders Love Right Now

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume